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Background: To compare the incidence and timing of bone fractures in postmenopausal women treated with 5
years of adjuvant tamoxifen or letrozole for endocrine-responsive early breast cancer in the Breast International Group
(BIG) 1-98 trial.
Methods: We evaluated 4895 patients allocated to 5 years of letrozole or tamoxifen in the BIG 1-98 trial who received
at least some study medication (median follow-up 60.3 months). Bone fracture information (grade, cause, site) was
collected every 6 months during trial treatment.
Results: The incidence of bone fractures was higher among patients treated with letrozole [228 of 2448 women
(9.3%)] versus tamoxifen [160 of 2447 women (6.5%)]. The wrist was the most common site of fracture in both
treatment groups. Statistically significant risk factors for bone fractures during treatment included age, smoking
history, osteoporosis at baseline, previous bone fracture, and previous hormone replacement therapy.
Conclusions: Consistent with other trials comparing aromatase inhibitors to tamoxifen, letrozole was associated with
an increase in bone fractures. Benefits of superior disease control associated with letrozole and lower incidence of
fracture with tamoxifen should be considered with the risk profile for individual patients.
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introduction
Aromatase inhibitors (AIs) profoundly lower circulating
estrogen levels in postmenopausal women [1, 2], predisposing
them to increased bone loss and fracture risk, while tamoxifen
has a protective effect on bone loss in postmenopausal women
[3]. The increase of bone fractures for patients who receive AIs
compared with tamoxifen is described in all recent adjuvant
trials comparing AIs to tamoxifen in postmenopausal breast
cancer patients, including the Breast International Group (BIG)
1-98 trial [4–10]. All these studies consistently show that AIs
are associated with superior disease control compared with
tamoxifen. In 2004, an expert panel of the American Society of
Clinical Oncology, after review of the published data,
recommended including an AI in the adjuvant setting either as
initial treatment or after treatment with tamoxifen for adjuvant
hormonal therapy for postmenopausal women with hormone
receptor-positive breast cancer [11]. Apart from AIs being
regarded as part of routine adjuvant therapy for
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in combination with ovarian suppression in premenopausal
breast cancer patients and even for prevention. It is therefore
important to thoroughly evaluate these newer agents for side-
effects. Postmenopausal women naturally experience increased
bone loss and are at risk of fractures, which can severely impact
their quality of life and impair their ability to cope with the
activities of daily life. Any increase in this risk is of importance
in evaluating the costs and benefits of AIs in adjuvant therapy.
Most of the large clinical trials involving AIs compared an AI
to the standard agent tamoxifen, either as 5 years of initial
therapy [4, 5, 10] or after 2–3 years of tamoxifen [6, 7, 12]. Bone
loss and increased fracture rates for the patients who received an
AI have been observed in all these trials, and any difference in
bone loss might partially reflect the protective effect of tamoxifen
[3]. In the MA.17 trial comparing letrozole to placebo in patients
who had received 5 years of tamoxifen, there was no statistically
significant difference in the clinical fracture incidence or in
reported osteoporosis [13], but a bone substudy concluded that
in this setting letrozole caused a modest increase in bone
resorption and reduction in bone mineral density (BMD) in the
spine and hip compared with placebo [14]. A recent update that
accounted for patients from the control group who were offered
to switch from placebo to letrozole after the results were known
reported a statistically significant increase in bone fractures
among those patients who switched to letrozole compared with
those who remained on placebo [15]. A recent published review
summarized the clinical and preclinical data regarding the effects
of AIs on BMD, markers of bone turnover, and clinical fracture
rates [16].
In this study, we investigate the incidence and timing of bone
fractures for patients on letrozole compared with tamoxifen in
the BIG 1-98 trial and develop a risk profile of patients more
likely to have a bone fracture while on treatment.
methods
BIG study 1-98 is a phase 3, double-blind trial to evaluate the effect of
letrozole compared with tamoxifen administered postoperatively to patients
with operable breast cancer. From March 1998 to May 2003, 8010
postmenopausal women with hormone receptor-positive invasive breast
cancer were randomized to one of the four following options: monotherapy
with tamoxifen (20 mg daily) for 5 years, letrozole (2.5 mg daily) for
5 years, sequential therapy comprising tamoxifen for 2 years followed by
letrozole for 3 years, or letrozole for 2 years followed by tamoxifen for
3 years. Patients were enrolled in the two-arm option of letrozole or
tamoxifen from March 1998 to March 2000 and the four-arm option from
April 1999 to May 2003. The current analysis focuses on the 4895 patients
who were randomized to the two monotherapy arms (two- and four-arm
options) in BIG 1-98 and received at least some study medication.
The study was coordinated by the International Breast Cancer Study
Group (IBCSG) on behalf of the BIG. The ethics committees and required
health authorities of each participating center approved the study protocol,
and all patients gave written informed consent. Details of study conduct
and results of the primary core analysis of the comparison of letrozole to
tamoxifen using data from patients randomized to all four arms [4] and
results from patients randomized to the two monotherapy arms [8] have
been previously reported.
The trial case report forms collected specific information on bone
fractures every 6 months during trial treatment, including grade, date, cause
(osteoporosis, metastasis, trauma, other), and site. Bone fractures were
graded as grade 2 (fracture not requiring surgery) or grade 3 (fracture
requiring surgery). All bone fractures were centrally reviewed by the
medical review team (MR and HH) at the IBCSG Coordinating Center and
investigators were asked to provide details of the cause of the fracture.
Particular attention was given to the adequacy of the traumas to the
presence of osteoporosis, assessment tools used to measure the bone
density, and concomitant medication or condition promoting bone loss.
The trial protocol mentioned that the use of bisphosphonates was
permitted and should be recorded, but it did not make any
recommendation with regard to the identification of risk factors for
osteoporosis, measurement of BMD, or the use of calcium or vitamin D
supplements.
The end point in this study was any bone fracture. In addition, we
evaluated causes of fracture as recorded in the case report form, including
osteoporosis, trauma, and metastasis, but because of small numbers and
lack of clear definitions, these are not presented. Only fractures occurring
during study medication were included. The 425 patients (17%)
randomized to receive 5 years of tamoxifen but who chose to crossover to
letrozole (subsequent to the publication of initial efficacy results and
according to addendum 5 of the protocol) are included in the analysis but
only fractures up to the time patients went off tamoxifen treatment were
considered.
The baseline characteristics listed in Table 1 were collected at study entry
and were compared between treatments using two-sided Fisher’s exact tests
[17] and two sample t-tests. Baseline risk factors examined for potential
increased risk of bone fracture included treatment allocation, age, body
mass index (BMI), smoking history, prior osteoporosis and prior bone
fracture. Subpopulation treatment effect pattern plots (STEPPs) were used
to investigate the pattern of differences in incidence of bone fractures
between treatment arms according to patient age at study entry [18, 19]. In
these plots, the y-axis shows the incidence (percentage) of bone fractures for
each treatment group. The incidence rates per 1000 women-years were also
provided for each treatment group, calculated either allowing only one
fracture per patient or including all fractures in patients who had multiple





Mean age, years (SD) 61.9 (8.0) 61.7 (7.8)





History of bisphosphonates use
No 98.9 98.7
Yes 1.1 1.3








Within the last 3 months 16.6 18.8
>3 months ago but <5 years 12.9 13.0
5 years ago or more 5.5 5.3
SD, standard deviation; HRT, hormone replacement therapy
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fractures during treatment. The 95% exact confidence intervals of the
incidence rates per 1000 women-years were calculated based on a Poisson
distribution.
Time from randomization to the first report of the bone fracture was
compared via a stratified log-rank test, with strata defined by randomization
option (two arm or four arm) and chemotherapy (yes or no, based on the
stratum at randomization and combining the two chemotherapy strata [4]).
Cox proportional hazards models were used to compare time to first bone
fracture of a given type between the treatment groups [20]. These models
were also stratified by randomization option and chemotherapy. In the
univariate Cox model, only treatment effect was included. To test the
interactions of treatment by a specific risk factor, the Cox model including
the treatment group, the specific risk factor, and their interaction term was
used. A more extensive multivariate Cox model was also employed to
examine the treatment effect. Besides the treatment group, the model was
adjusted for potential risk factors such as age at randomization (‡55 versus
<55 years), BMI (‡30 versus < 30 kg/m2), smoking history, presence of
osteoporosis at baseline, previous history of bone fracture at baseline,
previous history of hormone replacement therapy (HRT) at baseline (no
versus yes), and whether or not the patient had received bisphosphonates
before the bone fracture (as a time-varying variable). The relatively young age
cut-off was used to separate patients who may have some continuing ovarian
function into the younger group. If >1.5% of patients had a missing value for
a particular covariate, an indicator for whether or not the covariate was
missing was included in the model.
Competing risk models with disease-free survival (DFS) events (disease
recurrence, secondary malignancy, and death without recurrence) as
competing events were also used to evaluate the treatment effects on time to
first bone fracture [21].
results
patients
The median follow-up for this analysis is 60.3 months. Of the
4895 patients, 2448 received letrozole and 2447 received
tamoxifen. Table 1 shows the baseline patient and disease
characteristics observed according to treatment group. The
groups were well balanced with no statistically significant
differences between them for any of the baseline characteristics.
bone fracture incidence
Table 2A gives the incidences of bone fractures and multiple
fractures by grade. The incidence of bone fractures overall was
higher among patients treated with letrozole [L: 228 of 2448
women (9.3%) versus T: 160 of 2447 women (6.5%)].
Incidence according to grade was similar. The incidence of
multiple bone fractures while on treatment was also higher
among patients treated with letrozole [L: 23 of 2448 women
(0.9%) versus T: 10 of 2447 women (0.4%)]. Table 2B shows
the incidence of bone fractures, per 1000 woman-years.
Figure 1 shows the incidences of bone fractures during
treatment according to age using the STEPP method. Patients
who received letrozole had a higher incidence of bone fractures
than patients who received tamoxifen. The pattern of differences
in bone fracture incidence was generally consistent with regard
to age at study entry, with relatively smaller differences for
patients aged <55 and relatively larger differences for patients
from 59 to 69 years old (Figure 1). The incidence of bone
fractures was higher in older patients in both treatment arms.
sites of bone fractures
In the letrozole group, the most frequently observed sites of
fractures were wrist (68 patients), femur (33 patients), thoracic
spine (27 patients), humerus (25 patients), and ankle (21
patients). In the tamoxifen group, the most frequently observed
sites of fractures were wrist (34 patients), thoracic spine (22
patients), rib (22 patients), and ankle (14 patients) (Table 3).
time to first bone fracture
A forest plot of hazard ratios for time to first bone fracture for
all patients and various subgroups based on univariate Cox
models is shown in Figure 2. Under letrozole, there were
significantly more bone fractures (P = 0.002) than under
tamoxifen. This difference remained consistent across most of
the factors examined. Patients who received letrozole had more
bone fractures regardless of whether their BMI ‡30 kg/m2
(interaction P = 0.61), whether they had smoking history
Table 2. Incidence of bone fractures
Letrozole (N = 2448) Tamoxifen (N = 2447) Total (N = 4895)
N % N % N %
A: According to grade
Fractures
None 2220 90.7 2287 93.5 4507 92.1
Grade 2a 147 6.0 118 4.8 265 5.4
Grade 3 81 3.3 42 1.7 123 2.5
Any fracture (grade 2 or 3) 228 9.3 160 6.5 388 7.9
Multiple fractures
Grade 2a 11 0.4 6 0.2 17 0.3
Grade 3 12 0.5 4 0.2 16 0.3
Any multiple fractures 23 0.9 10 0.4 33 0.7
B: Incidence rates per 1000 woman-years (95% CI)
Allowing one fracture per patient 25.21 (22.04–28.70) 18.10 (15.41–21.14)
Allowing multiple fractures per patient 27.08 (23.86–30.61) 18.72 (16.02–21.75)
aGrade 2: fracture not requiring surgery; grade 3: fracture requiring surgery.
CI, confidence interval.
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(interaction P = 0.74), history of osteoporosis (interaction
P = 0.77), history of bone fracture (interaction P = 0.99),
received bisphosphonates before randomization (interaction
P = 0.42), or received HRT before randomization (interaction
P = 0.93). As shown on the forest plot (Figure 2), letrozole
resulted in more bone factures in patients >55 years old.
However, the interaction of treatment by age category is not
significant (P = 0.19).
Adjusting for potential risk factors, the treatment effects
predictive of bone fracture from a multivariate Cox model
(P = 0.001, Table 4) were consistent with those found in univariate
models (P= 0.002). The statistically significant risk factors for bone
fractures while on treatment included age >55 at randomization
(P = 0.01), smoking history (P = 0.05), presence of osteoporosis at
baseline (P = 0.01), previous history of bone fracture at baseline
(P < 0.0001), and previous history of HRT at baseline (P = 0.04).
Whether or not the patient had received bisphosphonates before
the bone fracture (157 patients randomized to letrozole and 128
to tamoxifen received bisphosphonates before bone fracture) was
not significantly associated with the occurrence of bone fracture
(P = 0.24).
Figure 3 presents the cumulative incidence of bone fracture,
making allowance for a DFS event as a competing risk event.
Competing risk models confirmed the results of the Cox
models, showing significantly more or earlier occurrence of
bone fractures in patients receiving letrozole (P = 0.0004).
discussion
In this study population, the overall incidence of bone fracture
was higher during treatment with letrozole, which is consistent
with previous reports from other trials analyzing adjuvant
treatment with AIs in postmenopausal women. The most recent
update of the Arimidex, Tamoxifen Alone or in Combination
(ATAC) trial [22], which is most closely similar in design to the
monotherapy comparisons from BIG 1-98 in the present
report, confirms the relative increased fracture rate of 55% for
women during treatment with anastrozole.
Studies involving switch to an AI after prior tamoxifen may
be more difficult to compare with ATAC or BIG 1-98 since the
initial tamoxifen may have served to strengthen bone [3]. In
contrast to the recent report of the International Exemestane
Study (IES) [6], which tested the AI exemestane after 2 or 3
years of tamoxifen given before randomization, we found the
higher incidence of fracture in women treated with an AI to be
independent of baseline conditions (osteoporosis, previous
bone fracture). Furthermore, the reported incidence of bone
fracture per 1000 women-years among patients assigned to
letrozole in the present study (27.08 per 1000 woman-years) is
higher than the 19.2 per 1000 woman-years described in
patients assigned exemestane [6]. Another difference between
the findings of IES and BIG 1-98 is the frequency of hip, wrist,
and spine fractures. These were rare in the IES report, in which
the large majority of fractures were at other sites [9]. In
contrast, we found that typically bone loss driven fractures (hip,
wrist, and spine) accounted for 53.5% of patients who had
fractures (122 of 228) during treatment with letrozole, and in
particular wrist fractures made up 29.8% of all patients
assigned to letrozole who had a bone fracture (68 of 228). In
the MA.17 trial, in which letrozole or placebo followed previous
treatment with tamoxifen, despite decreased BMD, the rate of
bone fracture was not significantly higher with letrozole [23].
Adjuvant treatment with AIs has been shown to improve
outcome in postmenopausal women with early breast cancer
and their use is steadily increasing. For this reason, it is
important to recognize and if possible prevent adverse events.
As illustrated in Figure 3, the trade-off between increased DFS
with letrozole and increased risk of bone fractures with
letrozole needs to be considered. The benefits of superior
disease control associated with letrozole and lower incidence of
fracture with tamoxifen should be considered with the risk
profile for each individual patient. Bone loss and subsequent
bone fractures may be avoided by accurately selecting and


























Median Age in Subpopulations (years)
Figure 1. Subpopulation treatment effect pattern plot analysis of
incidence of any bone fracture for letrozole versus tamoxifen among
overlapping subpopulations defined according to age at study entry.
Table 3. Sites of bone fractures
Site of bone fracturea Letrozole (N = 2448) Tamoxifen (N = 2447)
N % N %
Lower limb
Ankle 21 0.9 14 0.6
Femur 33 1.3 12 0.5
Tibia 9 0.4 9 0.4
Otherb 15 0.6 13 0.5
Upper limb
Wrist 68 2.8 34 1.4
Humerus 25 1.0 13 0.5
Radius/ulna 15 0.6 8 0.3
Otherc 19 0.8 12 0.5
Spine 27 1.1 22 0.9
Pelvis 11 0.4 6 0.2
Rib 13 0.5 22 0.9
Clavicle 3 0.1 5 0.2
Otherd 4 0.2 5 0.2
aIndividual patient may be counted more than once.
bPatella, fibula, metatarsal, toe, knee, and foot (not specified).
cMetacarpal, thumb, phalanx, elbow, olecranon, shoulder, scapula, and
forearm (not specified).
dNose, sternum, occipital, mandibula, and zygoma.
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for bone loss. This systematic evaluation should include risk
factors such as those identified in this study, especially age,
smoking history, osteoporosis, history of bone fracture, and
history of HRT use, though this latter association may be due to
a confounding of HRT use with decline in BMD.
In this trial, patients were not encouraged to take vitamin D
and calcium for bone health, and no standardized guidelines for
bisphosphonates use were recommended. More recent
guidelines suggest routine recommendation of calcium and
vitamin D supplements, plus baseline BMD measurement, with
follow-up if the initial result is in the osteopenic range [9].
Application of these guidelines would be likely to reduce the
excess risk of bone fracture associated with AI use in future
[24]. Meanwhile, the recognition of risk factors associated with
increased fracture risk may assist in reaching a clinical balance
Figure 2. Univariate Cox model analysis (hazard ratios for time to first bone fracture; letrozole versus tamoxifen) for relevant risk factors among patients
with any bone fracture. The box size is proportional to the inverse of the standard error of the hazard ratio estimates. The horizontal line gives the 95%
confidence interval.
Table 4. Time to first bone fracture
Multivariate Cox model results
Hazard ratio 95% CI P value
Bone fracture
Treatment (letrozole) 1.40 1.14–1.71 0.001
Age ‡ 55 years 1.48 1.10–2.00 0.01
BMI ‡ 30 kg/m2 0.96 0.75–1.23 0.76
Missing BMI 0.90 0.52–1.54 0.70








HRT before randomization 1.25 1.01–1.54 0.04
CI, confidence interval; BMI, body mass index; HRT, hormone replacement
therapy.
Figure 3. Cumulative incidence of first bone fracture with first disease-
free survival (DFS) event as competing events. In the competing risk
analysis, for patients who had DFS events before the first bone fracture, the
probability of bone fracture at a later time (after the DFS event) was
assumed to be zero.
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between the superior antitumor efficacy of AIs over tamoxifen
and the risks of bone fracture.
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